Eli Lilly's Weight-Loss Pill 'Zepbound' to Launch in Israel

The American pharmaceutical giant Eli Lilly's new weight-loss medication, known medically as tirzepatide and marketed as Zepbound, will be available in Israel starting September 15. Israel is the fourth country globally to approve the drug's marketing, following the United States, the United Kingdom, and the United Arab Emirates. The pill, taken once daily, is designed for adults with obesity or overweight individuals with at least one weight-related comorbidity, in conjunction with a reduced-calorie diet and increased physical activity.

Dr. Raz Haguel, director of the Obesity Treatment Medical Center, highlighted the convenience of the oral medication compared to injections, noting it can be taken without regard to meals, fasting, or specific drinking schedules. This ease of use, he explained, makes it a more accessible treatment option for long-term management of obesity, allowing for better patient adherence and personalized treatment plans.

Zepbound is a small molecule that is absorbed in the digestive system and does not require refrigeration, a significant logistical advantage for patients and the supply chain. The drug is administered in six different dosages, with prices ranging from approximately 691.59 shekels for the 0.8 mg and 2.5 mg doses to 1,146.46 shekels for the 14.5 mg and 17.2 mg doses. The medication has been submitted for approval to the Israeli Ministry of Health and is under consideration for inclusion in the national health basket.